BioNTech lifts 2021 COVID-19 vaccine output target to 2 billion doses
BioNTech has lifted its target for vaccine production to 2 billion doses in 2021, up from 1.3 billion doses earlier, thanks to new production facilities and efficiency gains. Julian Satterthwaite reports.
UP NEXT
UP NEXT
-
Germany to ease COVID-19 curbs, ramp up vaccinations
Reuters
-
Merck to help make Johnson & Johnson's COVID-19 vaccine: White House official
Reuters
-
Merck to help make Johnson & Johnson's COVID-19 vaccine: White House official
Reuters
-
New U.S. COVID-19 cases hit plateau after steep drops
Reuters
-
Global COVID-19 infections up for first time in seven weeks, WHO says
Reuters
-
U.S. downplays possibility of sharing COVID-19 vaccines with Mexico
Reuters
-
J&J COVID-19 vaccine shipping to U.S., but new deliveries hinge on regulators
Reuters
-
More than 20 million in Britain get first COVID-19 vaccine dose
Reuters
-
Fauci urges Americans to get any of the three COVID-19 vaccines available
Reuters
-
Fauci urges Americans to get any of the three COVID-19 vaccines available
Reuters
-
Exclusive: Mexico's president expected to ask Biden to share U.S. vaccines, say sources
Reuters
-
"Things are tenuous," U.S. CDC says as downward trend in COVID-19 cases stalls
Reuters
-
UK to prioritise next stage of COVID-19 vaccines by age, not job
Reuters
-
Advisory panel says FDA should authorize Johnson & Johnson COVID-19 vaccine
Reuters
-
FDA advisory panel to review Johnson & Johnson COVID-19 vaccine with thumbs up expected
Reuters
-
Advisory panel unanimously recommends FDA authorize Johnson & Johnson COVID-19 vaccine
Reuters